Sat, Aug 23, 2014, 3:14 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Savient Pharmaceuticals, Inc. Message Board

  • Ultimate_Conundrum Ultimate_Conundrum Feb 10, 2000 7:13 PM Flag

    Anyone else receive...

    ...the Warburg Dillon Read research in the mail?

    Interesting 28-page read.

    Comments/thoughts?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I have not received the Warburg paper work you refer to. Is it somthing dealing with BTGC?
      Dave

      • 1 Reply to nowmac
      • Draxis Health Starts Phase III Fibrimage
        Trials
        MISSISSAUGA, Ont. -- Draxis Health Inc. (DRAX)
        said its Draximage Inc. radiopharmaceutical subsidiary
        has started Phase III
        clinical trials in Canada
        for Fibrimage, a diagnostic tool for deep vein
        thrombosis, or DVT.
        In a news release, the drug company
        said the trial should involve 130 patients and be
        completed by the end of the year.
        DVTs are blood clots
        that form in the lower limbs and can lead to a
        pulmonary embolism, or a blockage of blood flow to the
        lungs, a
        condition that kills about 200,000 people a
        year in the U.S., it said.
        It said Fibrimage is
        based on Fibrin Binding Domain, a recombinant
        polypeptide developed by Bio-Technology General Corp.

        (BTGC) and licensed to Draximage on an exclusive,
        worldwide basis

    • Is this something you ordered, or was it
      delivered via BTGC? If the latter, I'm a street-name
      shareholder, so it sometimes takes a while to get things
      forwarded via my broker.

      If the former, I'd be
      interested in any synopsis you may care to post, or if you
      think it's really worthwhile, I might want to order it
      myself.

      Thanks

      • 2 Replies to Isnuffy
      • This isthe story that appeared in late December
        1999. It clearly states the 4th quarter will be a loss.
        Total earnings for year around 26 cents a share.
        Already earned about 29. Therefore a loss of a few cents
        in the cards for the 4th quarter.


        ISELIN,
        N.J.--(BUSINESS WIRE)--Dec. 29, 1999--Bio-Technology General
        Corp.
        (NASDAQ:BTGC - news) today commented that it anticipates full
        year 1999 revenues of
        approximately $84 million
        compared to $77 million in 1998. Despite the growth in
        revenues,
        earnings for the year are expected to be between $0.08 and
        $0.11 lower than the 1998 EPS of
        $0.36. The
        Company's revenue growth and EPS were adversely impacted by
        the previously
        announced reduction of Oxandrin�
        inventory, amounting to more than $15 million, by
        the
        Company's distributor for the product, Olsten Health
        Services, Inc. Additional contract revenues
        from new
        strategic alliances anticipated to be concluded by the end
        of the fourth quarter were
        expected to cover much
        of the Oxandrin inventory-related shortfall. While
        not yet concluded, the
        Company is continuing to
        pursue these new relationships.

        In commenting on
        the anticipated results, Sim Fass, Chairman and CEO
        of Bio-Technology General
        Corp., stated: ``The
        1999 results essentially reflect the impact of what we
        believe to be a temporary
        inventory adjustment
        situation. With Oxandrin prescriptions up by 28% in the
        first eleven months of
        1999 compared to the first
        eleven months of 1998, and end user sales for the full
        year 1999
        expected to be up by 24%, our Oxandrin
        business continues to demonstrate robust growth.
        This
        should translate into a significant increase in Oxandrin
        sales to our distributor in 2000 as both
        the
        absorption of the excess inventory is completed, and sales
        to Olsten fully reflect the growing end
        user
        sales. Moreover, we anticipate further development of
        the commercial potential for Oxandrin,
        to be
        accomplished by an increase in the size of the Company's sales
        force and expansion of sales
        activity into the wound
        care sector.''

        Dr. Fass added: ``Several new
        key strategic alliances, some of which were expected
        to generate
        contract revenues in the fourth
        quarter of 1999, are in the process of advanced
        negotiations. We
        look forward to their consummation in 2000,
        and we remain very confident that 2000 will be
        a
        record year for BTG in terms of revenues, product sales,
        and earnings. We have every expectation
        that, with
        the inventory reduction completed and the current
        growth rate of our product sales, we will
        be able to
        deliver on our commitment of accelerated growth in
        2000.''

        Bio-Technology General Corp., a leading
        biopharmaceutical company, develops, manufactures and
        markets
        genetically engineered and other products for human health
        care. The Company's products
        are marketed in over
        thirty countries worldwide.

        Statements in this
        news release concerning the Company's business outlook
        or future economic
        performance, anticipated
        profitability, revenues, expenses or other financial items; and
        statements
        concerning assumptions made or expectations as to any future
        events, conditions, performance or
        other matters, are
        ``forward-looking statements'' as that term is defined under the
        Federal Securities
        Laws. Forward-looking statements
        are subject to risks, uncertainties and other factors
        which could
        cause actual results to differ
        materially from those stated in such statements. Such risks,
        uncertainties
        and factors include, but are not limited to, changes
        and delays in product development plans
        and
        schedules, customer acceptance of new products, changes in
        pricing or other actions by
        competitors, patents owned
        by the Company and its competitors, and general
        economic conditions,
        as well as other risks detailed in
        the Company's filings with the Securities and
        Exchange Commission.

    • You must have a pretty high opinion of
      yourself!

      I'd say riding this piece of s---- for 3 yrs at no
      gain is long enough. The 3 yrs stagnation speaks for
      itself regardless of the investor. Everyone's investment
      scenario/objectives/methods are different. If I'm so stupid and irresponsible
      then how'd I manage a 1300 % gain in my net position
      over the last 15 months?

    • http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=BTGC&script=800&layout=8

      Shouldn't they mention that? I mean, I know it's what we
      all expected, and Wall Street is forward-looking,
      hence the way this stock dropped to the 5s back in '98.
      (Or maybe 4, don't quite remember.)

      But that's
      a very confusing press release. If ya have to check
      out 3q numbers, and they don't give you quarterly
      results, not very fair.

    • You must be on cloud 9 with IDX ... followed it a
      few years ago ... had a good run back in '95 then a
      roller coaster the past few years ... almost a double
      this month alone ... now if MLOG can move ... i see
      you apparently are in that too, as it am (at 1 3/16)


      dave

    • < It's easier to lay the blame "poor
      management" >

      and then have some "poor" shareholder
      contact one of these pathetic law firms that files a
      class action ... claiming insider selling, unrealistic
      expectations, etc. ... as an example, i own REMC at 15 ...
      well, they had some tough times with far east
      situations 1+ years ago .. the stock is now 30-31 ... some
      bozo who bought near 30 a few years ago ... near the
      TOP ... felt he was wronged when the stock tanked to
      single digits ... and then the companies have to expend
      personnel and $$$ defending these lawsuits, most without
      any basis or merit ... sorry for the ranting and
      raving ... so frustrating wo watch/see others blame
      everybody but THEMSELF ...

    • Yes, the news was expected, but expectations
      don't feed the cat. This news should. :-) I'd been
      watching IDX for about 5 years, but only felt biometrics
      had turned a corner last year. My timing is getting a
      little better as I get older. :-)

      As for the
      LOG, well, I made a small fortune riding it from .88
      to almost 12 back in the mid-90's, and I only
      stepped back in last year at 1.75. I'm less hopeful this
      time around, but it's play money. My big bucks have
      always been wrapped around the biotechs.

    • I almost mentioned litigiousness in my earlier diatribe. Thanks for filling in the blank.

    • BTGC never posts Q4 numbers .. rather they just
      post 12 month totals ... forcing you or i to back out
      the cumulative numbers from Q3 to get the respective
      revs, EPS, etc. in Q4 ... never understood why they do
      this ...

    • As long as it's consistent.

      Seemed smarmy.

      (Don't really remember last year's.)

    • View More Messages
 
SVNTQ
0.00190.0000(0.00%)May 30 3:56 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.